One‐Pot Synthesis of Mono‐ and Disubstituted (3<i>H</i>)‐Quinazolin‐4‐ones in Dry Media Under Microwave Irradiation
作者:Minoo Dabiri、Peyman Salehi、Ali A. Mohammadi、Mostafa Baghbanzadeh
DOI:10.1081/scc-200048462
日期:2005.1
supported on silica gel is an efficient medium for one‐pot synthesis of (3H)‐quinazolin‐4‐ones in the absence of solvent undermicrowaveirradiation or classicalheating. The reaction of orthoesters with 2‐aminobenzamides ends up with the formation of monosubstituted (3H)‐quinazolin‐4‐ones. One‐pot synthesis of disubstituted (3H)‐quinazolin‐4‐ones is also achieved by the reaction of isatoic anhydride
Yb(OTf)<sub>3</sub>-CatalyzedOne-Pot Synthesis of Quinazolin-4(3<i>H</i>)-onesfrom Anthranilic Acid, Amines and Ortho Esters (or FormicAcid) in Solvent-Free Conditions
作者:Limin Wang、Jianjun Xia、Fang Qin、Changtao Qian、Jie Sun
DOI:10.1055/s-2003-39397
日期:——
An efficientsynthesis of an array of quinazolin-4(3 H)- ones from anthranilic acid, ortho esters (or formic acid) and amines using Yb(OTf)3 in one-pot undersolvent-freeconditions is de- scribed. Compared with the classical reactionconditions, this new synthetic method has the advantage of excellent yields (75-99%), shorter reaction time (few minutes) and reusability of the catalyst.
One-pot Synthesis of Substituted Quinazolin-4(3H)-ones under Microwave Irradiation
作者:Kurosh Rad-Moghadam、Mohammad S. Khajavi
DOI:10.1039/a802853b
日期:——
Synthesis of the title compounds by cyclocondensation of anthranilic acid, formic acid (or orthoesters) and an amine in one pot under microwave irradiation takes place in a few minutes.
在几分钟内在微波辐射下在一个罐中通过邻氨基苯甲酸,甲酸(或原酸酯)和胺的环缩合来合成标题化合物。
MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS
申请人:NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER
公开号:US20170014419A1
公开(公告)日:2017-01-19
Provided are a novel medicament for suppressing or preventing the metastasis of a malignant tumor such as carcinoma, a novel treatment or prevention method for suppressing or preventing the metastasis of a malignant tumor, etc. The medicament comprises a non-peptidic angiotensin type 2 receptor agonist as an active ingredient. In the medicament, the non-peptidic angiotensin type 2 receptor agonist may be, for example, a sulfonyl malonamide compound. The medicament may be a medicament for use in combination with an anticancer agent and/or an antitumor agent.